JORGE SALVADOR
Jorge Salvador has a degree in Pharmaceutical Sciences, (University of Coimbra) a master’s degree in Organic & Technological Chemistry, (New University of Lisbon), and a Ph.D. in Pharmacy-Pharmaceutical Chemistry (University of Coimbra in collaboration with the University of York, U.K.). He spent one year as a Postdoc student at the University of Sussex, UK. Post-grad. (1-year certif.) Cancer Biology & Therapeutics-HICR from Harvard-Medical School, University of Harvard, USA. He has a position as a Full Professor at the Faculty of Pharmacy of the University of Coimbra – Portugal and is a Non-Executive Member of the Board of CHEM4PHARMA, a start-up Pharmaceutical Company located in Portugal. Group leader of the research group “ Medicinal Chemistry & Drug Discovery” at the Center for Neuroscience and Cell Biology (CNC) at the University of Coimbra, Portugal.
His research group activity has been focused on studies of new semisynthetic steroid, diterpenoid, and triterpenoid derivatives with improved antitumor activity and investigation of their mechanisms of anticancer action. In addition, the discovery of novel PARP-1 inhibitors able to reverse anticancer chemoresistance and sensitize cancer cells to chemotherapy is another line of research. Furthermore, enzyme inhibitors able to tackle hormone-dependent cancers, such as 5alpha-reductase and CYP17 inhibitors on prostatic cancer, are pursued in the group as well as new anticancer drugs acting on ubiquitin-proteasome system (UPS). The green pharmaceutical processes, aiming to reach target molecules in a more efficient, eco-friendly, and cheaper manner are continuously pursued in the group. Quite recently, he has been involved in studies on pharmacophore and structure-based drug discovery for the rational design of lead compound inhibitors of BACE1 and Glutaminyl Cyclase for Alzheimer’s disease treatment. Recently, his research group started a new area of research related to the use of PROTACs in the treatment of cancer.
He has edited 3 books and published about 125 ISI journal papers, including Nat. Prod. Reports, Journal for ImmunoTherapy of Cancer, Briefings in Bioinformatics, J. Med. Chem., Eur. J. Med. Chem., Expert Opinion on Therapeutic Patents, Green Chemistry, Drug Discovery Today, among others, 16 book chapters and, 10 patents (2 US Patents granted). In addition, he is the author/co-author of more than 250 presentations at national and international conferences and workshops. Supervisor of 5 post-doc students, 22 Ph.D. students (15 concluded; 7 ongoings), and > 40 MSc students. Over the last few years, he has conducted several research projects in the field of pharmaceutical/medicinal chemistry & drug discovery which has contributed to his significant expertise in drug discovery.
-Member of evaluation committees from Fundação para a Ciência e a Tecnologia (FCT), the Portuguese Research Council and other international funding agencies, INSERM, (National Science Centre, Poland, Swiss National Science Foundation, Research Foundation-Flanders, Belgian, Czech Medical Research Agency, France, Argentine, Brazil, among others)
-Member of evaluation committees from A3ES.
-Reviewer of the European Research Council, ERC Advanced Grants.
- Arbitral Tribunal expert, (Industrial protection).
2014-Member of the Board of Directors of the MedChemTrain Ph.D. program, Univ. Coimbra.
2012-Group leader of the group “ Medicinal Chemistry & Drug Discovery” at the Center for Neuroscience and Cell Biology (CNC)
2015-Coordinator of the Master in Medicinal Chemistry
2010-2017; 2021- Coordinator of the Master in Industrial Pharmaceutical Chemistry
2016-Director of the Mass Spectrometry Unity, University of Coimbra
2015-Editorial Advisory Board of Current Green Chemistry
2019-Guest Editor of Frontiers in Oncology
2020-Editorial Board, Molecules, Medicinal Chemistry Section
2021-Editorial Board, International Journal of Molecular Sciences
2021-Member of the General Council of the University of Coimbra
2021-Head of Laboratory of Pharmaceutical/Medicinal Chemistry at FFUC
2024-Future President & President Elected of the Division of Medicinal Chemistry & Chemical Biology of the SPQ.
His research group activity has been focused on studies of new semisynthetic steroid, diterpenoid, and triterpenoid derivatives with improved antitumor activity and investigation of their mechanisms of anticancer action. In addition, the discovery of novel PARP-1 inhibitors able to reverse anticancer chemoresistance and sensitize cancer cells to chemotherapy is another line of research. Furthermore, enzyme inhibitors able to tackle hormone-dependent cancers, such as 5alpha-reductase and CYP17 inhibitors on prostatic cancer, are pursued in the group as well as new anticancer drugs acting on ubiquitin-proteasome system (UPS). The green pharmaceutical processes, aiming to reach target molecules in a more efficient, eco-friendly, and cheaper manner are continuously pursued in the group. Quite recently, he has been involved in studies on pharmacophore and structure-based drug discovery for the rational design of lead compound inhibitors of BACE1 and Glutaminyl Cyclase for Alzheimer’s disease treatment. Recently, his research group started a new area of research related to the use of PROTACs in the treatment of cancer.
He has edited 3 books and published about 125 ISI journal papers, including Nat. Prod. Reports, Journal for ImmunoTherapy of Cancer, Briefings in Bioinformatics, J. Med. Chem., Eur. J. Med. Chem., Expert Opinion on Therapeutic Patents, Green Chemistry, Drug Discovery Today, among others, 16 book chapters and, 10 patents (2 US Patents granted). In addition, he is the author/co-author of more than 250 presentations at national and international conferences and workshops. Supervisor of 5 post-doc students, 22 Ph.D. students (15 concluded; 7 ongoings), and > 40 MSc students. Over the last few years, he has conducted several research projects in the field of pharmaceutical/medicinal chemistry & drug discovery which has contributed to his significant expertise in drug discovery.
-Member of evaluation committees from Fundação para a Ciência e a Tecnologia (FCT), the Portuguese Research Council and other international funding agencies, INSERM, (National Science Centre, Poland, Swiss National Science Foundation, Research Foundation-Flanders, Belgian, Czech Medical Research Agency, France, Argentine, Brazil, among others)
-Member of evaluation committees from A3ES.
-Reviewer of the European Research Council, ERC Advanced Grants.
- Arbitral Tribunal expert, (Industrial protection).
2014-Member of the Board of Directors of the MedChemTrain Ph.D. program, Univ. Coimbra.
2012-Group leader of the group “ Medicinal Chemistry & Drug Discovery” at the Center for Neuroscience and Cell Biology (CNC)
2015-Coordinator of the Master in Medicinal Chemistry
2010-2017; 2021- Coordinator of the Master in Industrial Pharmaceutical Chemistry
2016-Director of the Mass Spectrometry Unity, University of Coimbra
2015-Editorial Advisory Board of Current Green Chemistry
2019-Guest Editor of Frontiers in Oncology
2020-Editorial Board, Molecules, Medicinal Chemistry Section
2021-Editorial Board, International Journal of Molecular Sciences
2021-Member of the General Council of the University of Coimbra
2021-Head of Laboratory of Pharmaceutical/Medicinal Chemistry at FFUC
2024-Future President & President Elected of the Division of Medicinal Chemistry & Chemical Biology of the SPQ.
less
Interests
Uploads
Papers by JORGE SALVADOR